Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: Severe GH deficiency (GHD) is associated with, increased cardiovascular risk and intima-media thickness (IMT) at major arteries. Objective: The objective of the study was to investigate the 5-yr effects of GH replacement on common carotid IMT and insulin resistance syndrome (IRS) (at least two of the following: triglycerides levels ≥ 1.7 mmol/liter, high-density lipoprotein-cholesterol levels ≤ 1.0 mmol/liter, blood pressure above 130/85 mm Hg, fasting glucose 6.1–7 or 2 hr after glucose 7.7–11.1 mmol/liter). Design: This was an interventional, open, prospective, controlled study. Patients: Patients included 35 men with severe GHD and 35 age-matched healthy men as controls. Intervention: All patients received standard replacement therapy; GH replacement was added in 22 patients (group A) and refused by 13 others (group B). Measurements: Five-year changes in IMT and IRS prevalence were measured. Results: At baseline, IMT was higher in the patients with (P < 0.001) and without IRS (P = 0.004) than in controls. Eighteen patients (51.4%) and two controls (5.7%; P < 0.0001) had IRS. At study end, use of lipid-lowering drugs (92.3, vs. 13.6 and 34.3%, P < 0.0001), glucose-lowering drugs (69.2 vs. 31.4 and 22.7%; P = 0.016), and antihypertensive drugs (61.5 vs. 20.0 and 4.5%; P < 0.0001) was higher in group B patients than controls and group A patients. IGF-I levels normalized in all group A patients and remained lower than −1 sd score in 77% of group B patients. IMT significantly decreased only in group A and significantly increased in controls and nonsignificantly in group B patients. IRS prevalence significantly reduced only in group A patients. Conclusions: Severely hypopituitary GHD men have more frequently increased IMT at common carotid arteries and IRS than controls. After 5 years, only in GH replaced patients, IMT and prevalence of IRS decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
American College of Endocrinology Position Statement on the Insulin Resistance Syndrome
Einhorn, D. (2003) · Endocrine Practice · doi:10.4158/ep.9.s2.5 · Cited by 1,066
Juul, A., Scheike, T., Davidsen, M., Gyllenborg, J., & Jørgensen, T. (2002) · Circulation · doi:10.1161/01.cir.0000027563.44593.cc · Cited by 640
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Markussis, V., Beshyah, S. A., Johnston, D. G., Fisher, C., Nicolaides, A. N., & Sharp, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)92892-j · Cited by 390
Laughlin, G. A., Barrett-Connor, E., Criqui, M. H., & Kritz-Silverstein, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030967 · Cited by 374
Aimaretti, G., Corneli, G., Razzore, P., Bellone, S., Baffoni, C., Arvat, E., Camanni, F., & Ghigo, E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4837 · Cited by 272
Growth Hormone and Cardiovascular Risk Factors
Gola, M., Bonadonna, S., Doga, M., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0545 · Cited by 135
Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle
Stewart, P. M., Toogood, A. A., & Tomlinson, J. W. (2001) · Hormone Research in Paediatrics · doi:10.1159/000048126 · Cited by 103 · cited 1×
“Moreover, GHD is associated with an increased cortisol to cortisone metabolite ratio and low-dose GH replacement reverses these abnormalities (34).”
BackgroundLeonsson, M., Hulthe, J., Oscarsson, J., Johannsson, G., Wendelhag, I., Wikstrand, J., & Bengtsson, B. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01663.x · Cited by 49
Cited by
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
“The reduction in atherosclerosis with use of GHRT has been assessed by several studies evaluating carotid IMT (Pfeifer et al., 1999; Leonsson et al., 2002; Murata et al., 2003; Colao et al., 2008).”
Method
Metadata
- Authors
- Colao, A., Di Somma, C., Spiezia, S., Savastano, S., Rota, F., Savanelli, M. C., & Lombardi, G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-09-01
- Volume
- 93
- Issue
- 9
- Pages
- 3416-3424
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2084969452
- Cited by
- 61
- References
- 10
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency. https://app.cochat.ai/papers/10.1210/jc.2007-2810
- The paper
- Colao, A., Di Somma, C., Spiezia, S., Savastano, S., Rota, F., Savanelli, M. C., & Lombardi, G. (2008). Growth Hormone Treatment on Atherosclerosis: Results of a 5-Year Open, Prospective, Controlled Study in Male Patients with Severe Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2007-2810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.